by 
Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects women of reproductive age. PCOS causes enlarged ovaries with small cysts on the outer edges. Some key signs and symptoms of PCOS include irregular or prolonged menstrual periods, excess hair growth (hirsutism), acne, pelvic pain, and difficulty getting pregnant. Diagnosis of PCOS involves physical exam, imaging tests, and blood tests to check hormone levels. The global PCOS diagnostic market is served by various diagnostic tests such as ultrasound, hormone blood tests, biopsy of ovarian tissue, and genetic testing.
The global PCOS diagnostic market is estimated to be valued at US$ 820 million in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing awareness of PCOS related conditions: Growing awareness about causes, symptoms and impact of PCOS is driving more women to get properly diagnosed. Public health campaigns are helping women understand importance of early diagnosis and treatment management of PCOS. Advanced diagnostic techniques: Introduction of advanced diagnostic techniques such as 3D ultrasound and computer-aided detection system imaging are positively impacting early detection of cysts and abnormalities related to PCOS. This is fueling growth of PCOS diagnostic market.
This increased awareness of PCOS and availability of advanced tests is expected to drive more women to opt for proper diagnosis and management of this complex hormonal condition.
Segment Analysis
The global PCOS diagnostic market is segmented on the basis of diagnostic type, end-user and region. Based on diagnostic type, the market is segmented into ovulation prediction kits, pelvic ultrasonography, diagnostic kits and insulin resistance testing. Among these, pelvic ultrasonography dominate the market owing to its high accuracy in detecting ovarian cysts and confirming PCOS. Ultrasound scan or imaging helps to observe the ovaries and check for cysts.
PEST Analysis
Political: Government initiatives to spread awareness about PCOS and related health issues positively impact the market growth.
Economic: Rising disposable incomes coupled with growing insurance coverage for diagnostic procedures boost the market.
Social: Increasing prevalence of lifestyle diseases like PCOS due to sedentary jobs, stress and changing eating habits support market expansion.
Technological: Advent of advanced diagnostic tools and home-use kits for early detection improve the patient access and market revenue.
Key Takeaways
The global PCOS diagnostic market is expected to witness high growth at a CAGR of 5.3% during the forecast period of 2023 to 2030.
Regional analysis comprises- North America dominates the market owing to established healthcare infrastructure and early technology adoption. Asia Pacific exhibits fastest growth due to growing medical tourism, rising healthcare spending and large patient pool.
Key players related content comprises- Key players operating in the PCOS diagnostic market are Abbott, Siemens, bioMérieux SA, Danaher, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd. and DiaSorin S.p.A. Key players are focusing on launching innovative diagnostic kits and tools to expand their market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
